Header Logo

Connection

Mark Tidswell to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Mark Tidswell has written about Dose-Response Relationship, Drug.
Mark Tidswell
Connection Strength
0.076
Dose-Response Relationship, Drug
  1. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010 Jan; 38(1):72-83.
    View in: PubMed
    Score: 0.076
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.